LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 76

Search options

  1. Book ; Online: Liver Cancer

    Feitelson, Mark / Arzumanyan, Alla

    Genesis, Progression and Metastasis

    2023  

    Keywords Oncology ; hepatocellular carcinoma ; liver cirrhosis ; inflammation ; biomarkers ; immunotherapy ; gene expression
    Language English
    Size 1 electronic resource (146 pages)
    Publisher IntechOpen
    Document type Book ; Online
    Note English
    HBZ-ID HT030381341
    ISBN 9781803564159 ; 1803564156
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Article: Editorial: Microbiome metabolites in health and disease.

    Canfora, Emanuel E / Feitelson, Mark A / Arzumanyan, Alla

    Frontiers in microbiology

    2023  Volume 14, Page(s) 1270001

    Language English
    Publishing date 2023-09-12
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2587354-4
    ISSN 1664-302X
    ISSN 1664-302X
    DOI 10.3389/fmicb.2023.1270001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Human viral oncogenesis: a cancer hallmarks analysis.

    Mesri, Enrique A / Feitelson, Mark A / Munger, Karl

    Cell host & microbe

    2014  Volume 15, Issue 3, Page(s) 266–282

    Abstract: ... the Hallmarks of Cancer framework of Hanahan and Weinberg (2000 and 2011) is used to dissect the viral, host ...

    Abstract Approximately 12% of all human cancers are caused by oncoviruses. Human viral oncogenesis is complex, and only a small percentage of the infected individuals develop cancer, often many years to decades after the initial infection. This reflects the multistep nature of viral oncogenesis, host genetic variability, and the fact that viruses contribute to only a portion of the oncogenic events. In this review, the Hallmarks of Cancer framework of Hanahan and Weinberg (2000 and 2011) is used to dissect the viral, host, and environmental cofactors that contribute to the biology of multistep oncogenesis mediated by established human oncoviruses. The viruses discussed include Epstein-Barr virus (EBV), high-risk human papillomaviruses (HPVs), hepatitis B and C viruses (HBV and HCV, respectively), human T cell lymphotropic virus-1 (HTLV-1), and Kaposi's sarcoma herpesvirus (KSHV).
    MeSH term(s) Carcinogenesis ; Host-Pathogen Interactions ; Humans ; Neoplasms/epidemiology ; Neoplasms/etiology ; Virus Diseases/complications
    Language English
    Publishing date 2014-02-15
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2278004-X
    ISSN 1934-6069 ; 1931-3128
    ISSN (online) 1934-6069
    ISSN 1931-3128
    DOI 10.1016/j.chom.2014.02.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Short-chain fatty acids in cancer pathogenesis.

    Feitelson, Mark A / Arzumanyan, Alla / Medhat, Arvin / Spector, Ira

    Cancer metastasis reviews

    2023  Volume 42, Issue 3, Page(s) 677–698

    Abstract: ... cells but not to surrounding tissue due to differences in their metabolic fate. Multiple hallmarks ...

    Abstract Cancer is a multi-step process that can be viewed as a cellular and immunological shift away from homeostasis in response to selected infectious agents, mutations, diet, and environmental carcinogens. Homeostasis, which contributes importantly to the definition of "health," is maintained, in part by the production of short-chain fatty acids (SCFAs), which are metabolites of specific gut bacteria. Alteration in the composition of gut bacteria, or dysbiosis, is often a major risk factor for some two dozen tumor types. Dysbiosis is often characterized by diminished levels of SCFAs in the stool, and the presence of a "leaky gut," permitting the penetration of microbes and microbial derived molecules (e.g., lipopolysaccharides) through the gut wall, thereby triggering chronic inflammation. SCFAs attenuate inflammation by inhibiting the activation of nuclear factor kappa B, by decreasing the expression of pro-inflammatory cytokines such as tumor necrosis factor alpha, by stimulating the expression of anti-inflammatory cytokines such as interleukin-10 and transforming growth factor beta, and by promoting the differentiation of naïve T cells into T regulatory cells, which down-regulate immune responses by immunomodulation. SCFA function epigenetically by inhibiting selected histone acetyltransferases that alter the expression of multiple genes and the activity of many signaling pathways (e.g., Wnt, Hedgehog, Hippo, and Notch) that contribute to the pathogenesis of cancer. SCFAs block cancer stem cell proliferation, thereby potentially delaying or inhibiting cancer development or relapse by targeting genes and pathways that are mutated in tumors (e.g., epidermal growth factor receptor, hepatocyte growth factor, and MET) and by promoting the expression of tumor suppressors (e.g., by up-regulating PTEN and p53). When administered properly, SCFAs have many advantages compared to probiotic bacteria and fecal transplants. In carcinogenesis, SCFAs are toxic against tumor cells but not to surrounding tissue due to differences in their metabolic fate. Multiple hallmarks of cancer are also targets of SCFAs. These data suggest that SCFAs may re-establish homeostasis without overt toxicity and either delay or prevent the development of various tumor types.
    MeSH term(s) Humans ; Dysbiosis ; Cytokines/metabolism ; Inflammation/metabolism ; Neoplasms/etiology ; Fatty Acids, Volatile/metabolism
    Chemical Substances Cytokines ; Fatty Acids, Volatile
    Language English
    Publishing date 2023-07-11
    Publishing country Netherlands
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 604857-2
    ISSN 1573-7233 ; 0167-7659
    ISSN (online) 1573-7233
    ISSN 0167-7659
    DOI 10.1007/s10555-023-10117-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book: Hepatitis C virus

    Feitelson, Mark

    from laboratory to clinic

    2002  

    Author's details Mark A. Feitelson
    Keywords Hepatitis
    Language English
    Size XIV, 256 S. : Ill.
    Publisher Cambridge Univ. Press
    Publishing place Cambridge
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT013327526
    ISBN 0-521-79959-7 ; 978-0-521-79959-1
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Article ; Online: TMEM43 promotes the development of hepatocellular carcinoma by activating VDAC1 through USP7 deubiquitination.

    Zhang, Nannan / Wang, Feiran / Yang, Xiaobing / Wang, Quhui / Chang, Renan / Zhu, Lirong / Feitelson, Mark A / Chen, Zhong

    Translational gastroenterology and hepatology

    2024  Volume 9, Page(s) 9

    Abstract: Background: Transmembrane protein 43 (: Methods: We utilized the RNA sequencing (RNA-seq) and The Cancer Genome Atlas (TGCA) databases to explore and identify genes that may play an important role in the occurrence and development of hepatocellular ... ...

    Abstract Background: Transmembrane protein 43 (
    Methods: We utilized the RNA sequencing (RNA-seq) and The Cancer Genome Atlas (TGCA) databases to explore and identify genes that may play an important role in the occurrence and development of hepatocellular carcinoma (HCC), such as
    Results: In this study, we utilized the RNA-seq and TGCA databases to mine data and found that
    Conclusions: Our study demonstrated that USP7 participates in the growth of HCC tumors through
    Language English
    Publishing date 2024-01-25
    Publishing country China
    Document type Journal Article
    ISSN 2415-1289
    ISSN (online) 2415-1289
    DOI 10.21037/tgh-23-108
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B.

    Feitelson, Mark A / Arzumanyan, Alla / Spector, Ira / Medhat, Arvin

    Biomedicines

    2022  Volume 10, Issue 9

    Abstract: Patients who are carriers of the hepatitis B virus (HBV) are at high risk of chronic liver disease (CLD) which proceeds from hepatitis, to fibrosis, cirrhosis and to hepatocellular carcinoma (HCC). The hepatitis B-encoded X antigen, HBx, promotes virus ... ...

    Abstract Patients who are carriers of the hepatitis B virus (HBV) are at high risk of chronic liver disease (CLD) which proceeds from hepatitis, to fibrosis, cirrhosis and to hepatocellular carcinoma (HCC). The hepatitis B-encoded X antigen, HBx, promotes virus gene expression and replication, protects infected hepatocytes from immunological destruction, and promotes the development of CLD and HCC. For virus replication, HBx regulates covalently closed circular (ccc) HBV DNA transcription, while for CLD, HBx triggers cellular oxidative stress, in part, by triggering mitochondrial damage that stimulates innate immunity. Constitutive activation of NF-κB by HBx transcriptionally activates pro-inflammatory genes, resulting in hepatocellular destruction, regeneration, and increased integration of the HBx gene into the host genome. NF-κB is also hepatoprotective, which sustains the survival of infected cells. Multiple therapeutic approaches include direct-acting anti-viral compounds and immune-stimulating drugs, but functional cures were not achieved, in part, because none were yet devised to target HBx. In addition, many patients with cirrhosis or HCC have little or no virus replication, but continue to express HBx from integrated templates, suggesting that HBx contributes to the pathogenesis of CLD. Blocking HBx activity will, therefore, impact multiple aspects of the host-virus relationship that are relevant to achieving a functional cure.
    Language English
    Publishing date 2022-09-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines10092210
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma.

    Medhat, Arvin / Arzumanyan, Alla / Feitelson, Mark A

    Oncotarget

    2021  Volume 12, Issue 24, Page(s) 2421–2433

    Abstract: Hepatitis B virus (HBV) is a human pathogen that has infected an estimated two billion people worldwide. Despite the availability of highly efficacious vaccines, universal screening of the blood supply for virus, and potent direct acting anti-viral drugs, ...

    Abstract Hepatitis B virus (HBV) is a human pathogen that has infected an estimated two billion people worldwide. Despite the availability of highly efficacious vaccines, universal screening of the blood supply for virus, and potent direct acting anti-viral drugs, there are more than 250 million carriers of HBV who are at risk for the sequential development of hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). More than 800,000 deaths per year are attributed to chronic hepatitis B. Many different therapeutic approaches have been developed to block virus replication, and although effective, none are curative. These treatments have little or no impact upon the portions of integrated HBV DNA, which often encode the virus regulatory protein, HBx. Although given little attention, HBx is an important therapeutic target because it contributes importantly to (a) HBV replication, (b) in protecting infected cells from immune mediated destruction during chronic infection, and (c) in the development of HCC. Thus, the development of therapies targeting HBx, combined with other established therapies, will provide a functional cure that will target virus replication and further reduce or eliminate both the morbidity and mortality associated with chronic liver disease and HCC. Simultaneous targeting of all these characteristics underscores the importance of developing therapies against HBx.
    Language English
    Publishing date 2021-11-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.28077
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Book: Hepatitis and chronic liver disease

    Feitelson, Mark

    (Clinics in laboratory medicine ; 16,2)

    1996  

    Author's details Mark A. Feitelson ..., guest ed
    Series title Clinics in laboratory medicine ; 16,2
    Collection
    Keywords Liver Diseases ; Hepatitis ; Chronische Leberinsuffizienz
    Subject Chronisches Leberversagen ; Gelbsucht ; Leberentzündung
    Language English
    Size XII S., S. 251 - 512 : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT007225477
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  10. Article ; Online: Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice.

    McBrearty, Noreen / Arzumanyan, Alla / Bichenkov, Eugene / Merali, Salim / Merali, Carmen / Feitelson, Mark

    Neoplasia (New York, N.Y.)

    2021  Volume 23, Issue 5, Page(s) 529–538

    Abstract: Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The HBV encoded oncoprotein, HBx, alters the expression of host genes and the activity of multiple signal transduction pathways ... ...

    Abstract Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The HBV encoded oncoprotein, HBx, alters the expression of host genes and the activity of multiple signal transduction pathways that contribute to the pathogenesis of HCC by multiple mechanisms independent of HBV replication. However, it is not clear which pathways are the most relevant therapeutic targets in hepatocarcinogenesis. Short chain fatty acids (SCFAs) have strong anti-inflammatory and anti-neoplastic properties, suggesting that they may block the progression of chronic liver disease (CLD) to HCC, thereby identifying the mechanisms relevant to HCC development. This hypothesis was tested in HBx transgenic (HBxTg) mice fed SCFAs. Groups of HBxTg mice were fed with SCFAs or vehicle from 6 to 9 months of age and then assessed for dysplasia, and from 9 to 12 months of age and then assessed for HCC. Livers from 12 month old mice were then analyzed for changes in gene expression by mass spectrometry-based proteomics. SCFA-fed mice had significantly fewer dysplastic and HCC nodules compared to controls at 9 and 12 months, respectively. Pathway analysis of SCFA-fed mice showed down-regulation of signaling pathways altered by HBx in human CLD and HCC, including those involved in inflammation, phosphatidylinositol 3-kinase, epidermal growth factor, and Ras. SCFA treatment promoted increased expression of the tumor suppressor, disabled homolog 2 (DAB2). DAB2 depresses Ras pathway activity, which is constitutively activated by HBx. SCFAs also reduced cell viability in HBx-transfected cell lines in a dose-dependent manner while the viability of primary human hepatocytes was unaffected. These unique findings demonstrate that SCFAs delay the pathogenesis of CLD and development of HCC, and provide insight into some of the underlying mechanisms that are relevant to pathogenesis in that they are responsive to treatment.
    MeSH term(s) Animals ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/metabolism ; Cell Line, Tumor ; Disease Models, Animal ; Disease Susceptibility ; Fatty Acids, Volatile/metabolism ; Gene Expression Regulation, Neoplastic ; Hepatitis B/complications ; Hepatitis B/virology ; Hepatitis B virus/physiology ; Humans ; Immunohistochemistry ; Liver Neoplasms/etiology ; Liver Neoplasms/metabolism ; Mice ; Mice, Transgenic ; Models, Biological ; Proteome ; Proteomics/methods ; Signal Transduction ; Trans-Activators/genetics ; Viral Regulatory and Accessory Proteins/genetics
    Chemical Substances Fatty Acids, Volatile ; Proteome ; Trans-Activators ; Viral Regulatory and Accessory Proteins ; hepatitis B virus X protein
    Language English
    Publishing date 2021-05-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1483840-0
    ISSN 1476-5586 ; 1522-8002
    ISSN (online) 1476-5586
    ISSN 1522-8002
    DOI 10.1016/j.neo.2021.04.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top